» Articles » PMID: 17241873

5-ASA Affects Cell Cycle Progression in Colorectal Cells by Reversibly Activating a Replication Checkpoint

Overview
Specialty Gastroenterology
Date 2007 Jan 24
PMID 17241873
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Individuals with inflammatory bowel disease are at risk of developing colorectal cancer (CRC). Epidemiologic, animal, and laboratory studies suggest that 5-amino-salicylic acid (5-ASA) protects from the development of CRC by altering cell cycle progression and by inducing apoptosis. Our previous results indicate that 5-ASA improves replication fidelity in colorectal cells, an effect that is active in reducing mutations. In this study, we hypothesized that 5-ASA restrains cell cycle progression by activating checkpoint pathways in colorectal cell lines, which would prevent tumor development and improve genomic stability.

Methods: CRC cells with different genetic backgrounds such as HT29, HCT116, HCT116(p53-/-), HCT116+chr3, and LoVo were treated with 5-ASA for 2-96 hours. Cell cycle progression, phosphorylation, and DNA binding of cell cycle checkpoint proteins were analyzed.

Results: We found that 5-ASA at concentrations between 10 and 40 mmol/L affects cell cycle progression by inducing cells to accumulate in the S phase. This effect was independent of the hMLH1, hMSH2, and p53 status because it was observed to a similar extent in all cell lines under investigation. Moreover, wash-out experiments demonstrated reversibility within 48 hours. Although p53 did not have a causative role, p53 Ser15 was strongly phosphorylated. Proteins involved in the ATM-and-Rad3-related kinase (ATR)-dependent S-phase checkpoint response (Chk1 and Rad17) were also phosphorylated but not ataxia telengectasia mutated kinase.

Conclusions: Our data demonstrate that 5-ASA causes cells to reversibly accumulate in S phase and activate an ATR-dependent checkpoint. The activation of replication checkpoint may slow down DNA replication and improve DNA replication fidelity, which increases the maintenance of genomic stability and counteracts carcinogenesis.

Citing Articles

Chemoprophylaxis of precancerous lesions in patients who are at a high risk of developing colorectal cancer (Review).

Ogurchenok N, Khalin K, Bryukhovetskiy I Med Int (Lond). 2024; 4(3):25.

PMID: 38628384 PMC: 11019464. DOI: 10.3892/mi.2024.149.


Recyclable mesalamine-functionalized magnetic nanoparticles (mesalamine/GPTMS@SiO@FeO) for tandem Knoevenagel-Michael cyclocondensation: grinding technique for the synthesis of biologically active 2-amino-4-benzo[]pyran derivatives.

Partovi M, Rezayati S, Ramazani A, Ahmadi Y, Taherkhani H RSC Adv. 2023; 13(48):33566-33587.

PMID: 38020042 PMC: 10658220. DOI: 10.1039/d3ra06560j.


Chemoprevention of Colitis-Associated Dysplasia or Cancer in Inflammatory Bowel Disease.

Hsiao S, Yen H, Chen Y Gut Liver. 2022; 16(6):840-848.

PMID: 35670121 PMC: 9668496. DOI: 10.5009/gnl210479.


Sodium salicylate and 5-aminosalicylic acid synergistically inhibit the growth of human colon cancer cells and mouse intestinal polyp-derived cells.

Takakura H, Horinaka M, Imai A, Aono Y, Nakao T, Miyamoto S J Clin Biochem Nutr. 2022; 70(2):93-102.

PMID: 35400827 PMC: 8921728. DOI: 10.3164/jcbn.21-74.


Promoting mechanism of serum amyloid a family expression in mouse intestinal epithelial cells.

Wakai M, Hayashi R, Ueno Y, Onishi K, Takasago T, Uchida T PLoS One. 2022; 17(3):e0264836.

PMID: 35303008 PMC: 8932556. DOI: 10.1371/journal.pone.0264836.


References
1.
Staerk Laursen L, Stokholm M, Bukhave K, Rask-Madsen J, Lauritsen K . Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut. 1990; 31(11):1271-6. PMC: 1378698. DOI: 10.1136/gut.31.11.1271. View

2.
Christensen L, Fallingborg J, Jacobsen B, Abildgaard K, Rasmussen H, Rasmussen S . Bioavailability of 5-aminosalicyclic acid from slow release 5-aminosalicyclic acid drug and sulfasalazine in normal children. Dig Dis Sci. 1993; 38(10):1831-6. DOI: 10.1007/BF01296106. View

3.
Koi M, Umar A, Chauhan D, Cherian S, Carethers J, Kunkel T . Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res. 1994; 54(16):4308-12. View

4.
Layer P, Goebell H, Keller J, Dignass A, Klotz U . Delivery and fate of oral mesalamine microgranules within the human small intestine. Gastroenterology. 1995; 108(5):1427-33. DOI: 10.1016/0016-5085(95)90691-6. View

5.
Bebenek K, Kunkel T . Analyzing fidelity of DNA polymerases. Methods Enzymol. 1995; 262:217-32. DOI: 10.1016/0076-6879(95)62020-6. View